Overview

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intoleran

Status:
Completed

Trial end date:
2017-08-03

Target enrollment:

Participant gender:

Summary

To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor (TNF) therapy.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Adjuvants, Immunologic
Immunologic Factors
Upadacitinib